Amyloidosis refers to a group of rare conditions characterized by abnormal protein deposits known as amyloid in tissues and organs. Amyloidosis can be hereditary or due to other chronic inflammatory conditions. The main types of amyloidosis include AL amyloidosis, AA amyloidosis, and ATTR amyloidosis. Diagnosis of amyloidosis involves blood tests, biopsy, and imaging tests. Amyloidosis diagnosis market comprises instruments, reagents & kits used for diagnosis through biochemical tests and histopathological examination of tissues. Amyloidosis diagnostics help in early detection and treatment monitoring in patients.
The AL amyloidosis diagnostic market is estimated to be valued at USD 1.068 billion in 2024 and is expected to reach USD 1.693 billion by 2031, growing at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031.
Key players operating in the amyloidosis diagnostic market are Siemens Healthineers, Pfizer Inc., Merck KGaA, Prothena Corporation plc, IONIS Pharmaceuticals among others.
The AL Amyloidosis Diagnostic Market provides various opportunities such as development of advanced diagnostics techniques such as biochip-based assays, development of panels for comprehensive diagnosis, and adoption of epigenetics approach for early detection.
The amyloidosis diagnostic market is witnessing global expansion due to increasing research collaborations, partnerships to develop novel diagnostics, and international conferences to spread awareness about amyloidosis.
Market drivers
Rising prevalence of amyloidosis and associated chronic diseases is a key market driver. According to the Amyloidosis Foundation, around 4,500 Americans are newly diagnosed with amyloidosis each year. Additionally, increasing research funding from public and private sources to develop innovative diagnostics is also fueling the market growth.
PEST Analysis
Political: Regulations regarding diagnostic testing vary across countries. Harmonization of regulations can help streamline disease diagnosis and management.
Economic: Cost of AL amyloidosis diagnosis and care pose a significant burden. Out of pocket costs may limit patient access to accurate and timely testing.
Social: Low disease awareness in general population can delay diagnosis. Education programs help promote understanding of early symptoms and benefits of prompt evaluation.
Technological: New blood tests and imaging techniques offer non-invasive options to biopsy. Advanced tools such as mass spectroscopy improve diagnostic accuracy. Development of sensitive and specific tests with results in hours instead of days can transform management.
Geographical Regions with Highest Market Value
North America and Europe account for over 70% share of the global market value due to advanced healthcare systems and widespread medical insurance coverage. High diagnostic rates in these regions is driven by better access to specialized amyloidosis care centers and newer testing options.
Fastest Growing Regional Market
The Asia Pacific market is expected to expand rapidly at a double digit CAGR. Growing economies in the region are investing heavily in healthcare infrastructure and diagnostic services. Simultaneously, improving public health initiatives in countries like China and India are leading to higher rates of diagnosis and treatment uptake for previously under diagnosed conditions such as AL amyloidosis.
Get this Report in Japanese Language: ALアミロイドーシス診断市場
Get this Report in Korean Language: AL 아밀로이드증 진단 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
